Arthritis & Rheumatology

OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, European Alliance, United, United Nations, Asthma, AAP, Yale school, CD74, Hôpital Cochin, Trinity College Dublin, Arthritis & Rheumatology, Molecular medicine, Cancer, University, Publication, Medical school, ASCI, Prognosis, Trinity, Pathology, Diagnosis, Public health, Trinity College, Arthritis, Physiology, Biomarker, Global Health, Nephritis, Society, EULAR, Inflammatory bowel disease, Physician, Pharmaceutical industry

OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.

Key Points: 
  • OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.
  • ON104 is a monoclonal antibody targeting the oxidized isoform of the macrophage migration inhibitory factor (oxMIF) for the treatment of chronic inflammatory diseases.
  • His research focuses on arthritis and other inflammatory rheumatic diseases, precision medicine, and the management of complex diseases.
  • Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics.

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

Retrieved on: 
Thursday, November 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, SLE, PSF, FDA, Insurance, American College, EGFR, U.S.–Canada Team Tournament (Go), Conversation, SG, EDGAR, SEDAR, American Society of Nephrology, AURORA, Nephrology, Lupus, Persistent environment, EC, Glomerular filtration rate, R, Society, Arthritis & Rheumatology, Bank statement, Growth, Risk, Marketing, Webcast, Analysis, Healthcare Improvement Scotland, American College of Rheumatology, Safety, LN, Investment, Management, Patient, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Rheumatology, Cryptocurrency, Pharmaceutical industry, Rare-earth element, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.
  • Total net revenue was $54.5 million for the three months ended September 30, 2023 and $55.8 million for the same period in 2022.
  • Financial Results for the Three and Nine Months Ended September 30, 2023
    Total net revenue was $54.5 million and $55.8 million for the three months ended September 30, 2023 and September 30, 2022, respectively.
  • Aurinia will host a conference call and webcast to discuss the quarter ended September 30, 2023 financial results today, Thursday, November 2, 2023 at 8:30 a.m.

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results

Retrieved on: 
Thursday, August 3, 2023
Biotechnology, Pharmaceutical, Health, Patent, MMF, SG, POT, European Renal Association, Marketing, PSF, Bank statement, Nephrology, AURORA, Conversation, J.P. Morgan & Co., Risk, EDGAR, LN, ERA, Proteinuria, European Alliance of Associations for Rheumatology, Orange Book, Arthritis & Rheumatology, Patient, Investment, Analysis, SEDAR, Rheumatology, Webcast, United Kingdom, Management, Growth, EULAR, R, Research, FDA, NICE, National Institute for Health and Care Excellence, Cryptocurrency, Pharmaceutical industry, Clothing, Aurinia, Swissmedic

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023.
  • Financial Results for the Three and Six Months Ended June 30, 2023
    Total net revenue was $41.5 million and $28.2 million for the three months ended June 30, 2023 and June 30, 2022, respectively.
  • Interest expense was $0.1 million for the three and six months ended June 30, 2023 due to the commencement of the monoplant finance lease during the second quarter of 2023.
  • Aurinia will host a conference call and webcast to discuss the quarter ended June 30, 2023 financial results today, Thursday, August 3, 2023 at 8:30 a.m.

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events

Retrieved on: 
Wednesday, July 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Maintenance, Kidney failure, Chronic kidney disease, Voclosporin, New York University Grossman School of Medicine, Glucocorticoid, Infection, Aes, AURORA, Clinical trial, EGFR, American College of Rheumatology, Glomerular filtration rate, New York University, Research, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Lupus, Kidney disease, Proteinuria, CRR, Arthritis & Rheumatology, MD, Patient, Division, American College, Safety, Pharmaceutical industry, Medicine, Rheumatology, LN, Aurinia, UPCR

“Proteinuria, a defining part of the characterization of chronic kidney disease, often precedes a decline in kidney function and is associated with progression to kidney failure.

Key Points: 
  • “Proteinuria, a defining part of the characterization of chronic kidney disease, often precedes a decline in kidney function and is associated with progression to kidney failure.
  • Reductions in proteinuria are critical for slowing or stopping progression to end-stage kidney disease and improving long-term outcomes for LN patients.
  • Notably, in this extension study, kidney preservation, sustained renal response, and reductions in steroid use were achieved with voclosporin.
  • We are proud of our sustained research in autoimmune diseases like lupus and remain committed to helping improve kidney health for people living with lupus nephritis.”

Fifth Update of ACR COVID-19 Vaccine Guidance Supports Fourth Doses for High-Risk Rheumatic Disease Patients

Retrieved on: 
Wednesday, February 2, 2022
Diagnosis, Patient, Bamlanivimab, Health, Bamlanivimab/etesevimab, American College, RNA transfection, Arthritis, Post-exposure prophylaxis, Omicron, Appendix, Rheumatology, Arthritis & Rheumatology, ACR, Research, Casirivimab/imdevimab, COVID-19, Vaccination, CDC, Practice management, Lists of diseases, Injection, GLOBE, Johnson & Johnson COVID-19 vaccine, Education, EUA, FDA, American College of Rheumatology, Rheumatism, Vaccine, Pharmaceutical industry

The guidance recommends that all rheumatic disease patients receive a booster dose after their primary vaccine series, as recommended by the CDC.

Key Points: 
  • The guidance recommends that all rheumatic disease patients receive a booster dose after their primary vaccine series, as recommended by the CDC.
  • These recommendations for primary vaccination, supplemental dosing, and booster doses apply regardless of whether patients have experienced natural COVID-19 infection.
  • It remains important for rheumatology providers to assess the vaccination status of all patients with rheumatic diseases, said Dr. Jeffrey Curtis, Chair of the ACR COVID-19 Vaccine Guidance Task Force.
  • Rheumatologists are experts in the diagnosis, management, and treatment of more than 100 different types of arthritis and rheumatic diseases.

TSI Healthcare Partners with Arizona Arthritis & Rheumatology Associates, P.C.

Retrieved on: 
Thursday, October 4, 2018
Medicine, Health, Arthritis & Rheumatology, Arthritis

TSI Healthcare was selected to be the sole software and support provider for Arizona Arthritis & Rheumatology Associates' PM software and rheumatology specific EHR software.

Key Points: 
  • TSI Healthcare was selected to be the sole software and support provider for Arizona Arthritis & Rheumatology Associates' PM software and rheumatology specific EHR software.
  • We are 90 days into our TSI Healthcare transition; the providers and staff are settling into the new system," says Angel Magar, CEO of Arizona Arthritis & Rheumatology Associates.
  • Arizona Arthritis & Rheumatology Associates is comprised of 39 providers with 8 locations and is one of the largest rheumatology practices in the nation.
  • This new strategic partnership between TSI Healthcare and Arizona Arthritis & Rheumatology Associates will allow both parties to continue to work towards improving the future of rheumatology.